COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight

Charles Auffray; Rudi Balling; Niklas Blomberg; Myrna C. Bonaldo; Bertrand Boutron; Samir Brahmachari; Christian Bréchot; Alfredo Cesario; Sai-Juan Chen; Karine Clément; Daria Danilenko; Alberto Di Meglio; Andrea Gelemanović; Carole Goble; Takashi Gojobori; Jason D. Goldman; Michel Goldman; Yi-Ke Guo; James Heath; Leroy Hood; Peter Hunter; Li Jin; Hiroaki Kitano; Bartha Knoppers; Doron Lancet; Catherine Larue; Mark Lathrop; Martine Laville; Ariel B. Lindner; Antoine Magnan; Andres Metspalu; Edgar Morin; Lisa F. P. Ng; Laurent Nicod; Denis Noble; Laurent Nottale; Helga Nowotny; Theresa Ochoa; Iruka N. Okeke; Tolu Oni; Peter Openshaw; Mehmet Oztürk; Susanna Palkonen; Janusz T. Paweska; Christophe Pison; Mihael H. Polymeropoulos; Christian Pristipino; Ulrike Protzer; Josep Roca; Damjana Rozman; Marc Santolini; Ferran Sanz; Giovanni Scambia; Eran Segal; Ismail Serageldin; Marcelo Bento Soares; Peter Sterk; Sumio Sugano; Giulio Superti-Furga; David Supple; Jesper Tegner; Mathias Uhlen; Andrea Urbani; Alfonso Valencia; Vincenzo Valentini; Sylvie van der Werf; Manlio Vinciguerra; Olaf Wolkenhauer; Emiel Wouters

doi:https://doi.org/10.12688/F1000RESEARCH.26098.1

COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight

Charles Auffray, Rudi Balling, Niklas Blomberg, Myrna C. Bonaldo, Bertrand Boutron, Samir Brahmachari, Christian Bréchot, Alfredo Cesario, Sai-Juan Chen, Karine Clément, Daria Danilenko, Alberto Di Meglio, Andrea Gelemanović, Carole Goble, Takashi Gojobori, Jason D. Goldman, Michel Goldman, Yi-Ke Guo, James Heath, Leroy HoodPeter Hunter, Li Jin, Hiroaki Kitano, Bartha Knoppers, Doron Lancet, Catherine Larue, Mark Lathrop, Martine Laville, Ariel B. Lindner, Antoine Magnan, Andres Metspalu, Edgar Morin, Lisa F. P. Ng, Laurent Nicod, Denis Noble, Laurent Nottale, Helga Nowotny, Theresa Ochoa, Iruka N. Okeke, Tolu Oni, Peter Openshaw, Mehmet Oztürk, Susanna Palkonen, Janusz T. Paweska, Christophe Pison, Mihael H. Polymeropoulos, Christian Pristipino, Ulrike Protzer, Josep Roca, Damjana Rozman, Marc Santolini, Ferran Sanz, Giovanni Scambia, Eran Segal, Ismail Serageldin, Marcelo Bento Soares, Peter Sterk, Sumio Sugano, Giulio Superti-Furga, David Supple, Jesper Tegner, Mathias Uhlen, Andrea Urbani, Alfonso Valencia, Vincenzo Valentini, Sylvie van der Werf, Manlio Vinciguerra, Olaf Wolkenhauer, Emiel Wouters

Pulmonology (AMC)

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) belongs to a subgroup of coronaviruses rampant in bats for centuries. It caused the coronavirus disease 2019 (COVID-19) pandemic. Most patients recover, but a minority of severe cases experience acute respiratory distress or an inflammatory storm devastating many organs that can lead to patient death. The spread of SARS-CoV-2 was facilitated by the increasing intensity of air travel, urban congestion and human contact during the past decades. Until therapies and vaccines are available, tests for virus exposure, confinement and distancing measures have helped curb the pandemic. Vision: The COVID-19 pandemic calls for safeguards and remediation measures through a systemic response. Self-organizing initiatives by scientists and citizens are developing an advanced collective intelligence response to the coronavirus crisis. Their integration forms Olympiads of Solidarity and Health. Their ability to optimize our response to COVID-19 could serve as a model to trigger a global metamorphosis of our societies with far-reaching consequences for attacking fundamental challenges facing humanity in the 21st century. Mission: For COVID-19 and these other challenges, there is no alternative but action. Meeting in Paris in 2003, we set out to "rethink research to understand life and improve health." We have formed an international coalition of academia and industry ecosystems taking a systems medicine approach to understanding COVID-19 by thoroughly characterizing viruses, patients and populations during the pandemic, using openly shared tools. All results will be publicly available with no initial claims for intellectual property rights. This World Alliance for Health and Wellbeing will catalyze the creation of medical and health products such as diagnostic tests, drugs and vaccines that become common goods accessible to all, while seeking further alliances with civil society to bridge with socio-ecological and technological approaches that characterise urban systems, for a collective response to future health emergencies.

Original language	English
Pages (from-to)	1-18
Number of pages	18
Journal	F1000Research
Volume	9
DOIs	https://doi.org/10.12688/F1000RESEARCH.26098.1
Publication status	Published - 2021

Keywords

COVID-19
Coalition
Coronavirus
Pandemic
SARS-CoV-2
Solidarity
Systemic crisis
Systemic response

Access to Document

https://doi.org/10.12688/F1000RESEARCH.26098.1

Cite this

Auffray, C., Balling, R., Blomberg, N., Bonaldo, M. C., Boutron, B., Brahmachari, S., Bréchot, C., Cesario, A., Chen, S.-J., Clément, K., Danilenko, D., Meglio, A. D., Gelemanović, A., Goble, C., Gojobori, T., Goldman, J. D., Goldman, M., Guo, Y.-K., Heath, J., ... Wouters, E. (2021). COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight. F1000Research, 9, 1-18. https://doi.org/10.12688/F1000RESEARCH.26098.1

@article{e51045594eaf4d4b94468ba4983bcc47,

title = "COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity{\textquoteright}s fight",

abstract = "Background: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) belongs to a subgroup of coronaviruses rampant in bats for centuries. It caused the coronavirus disease 2019 (COVID-19) pandemic. Most patients recover, but a minority of severe cases experience acute respiratory distress or an inflammatory storm devastating many organs that can lead to patient death. The spread of SARS-CoV-2 was facilitated by the increasing intensity of air travel, urban congestion and human contact during the past decades. Until therapies and vaccines are available, tests for virus exposure, confinement and distancing measures have helped curb the pandemic. Vision: The COVID-19 pandemic calls for safeguards and remediation measures through a systemic response. Self-organizing initiatives by scientists and citizens are developing an advanced collective intelligence response to the coronavirus crisis. Their integration forms Olympiads of Solidarity and Health. Their ability to optimize our response to COVID-19 could serve as a model to trigger a global metamorphosis of our societies with far-reaching consequences for attacking fundamental challenges facing humanity in the 21st century. Mission: For COVID-19 and these other challenges, there is no alternative but action. Meeting in Paris in 2003, we set out to {"}rethink research to understand life and improve health.{"} We have formed an international coalition of academia and industry ecosystems taking a systems medicine approach to understanding COVID-19 by thoroughly characterizing viruses, patients and populations during the pandemic, using openly shared tools. All results will be publicly available with no initial claims for intellectual property rights. This World Alliance for Health and Wellbeing will catalyze the creation of medical and health products such as diagnostic tests, drugs and vaccines that become common goods accessible to all, while seeking further alliances with civil society to bridge with socio-ecological and technological approaches that characterise urban systems, for a collective response to future health emergencies.",

keywords = "COVID-19, Coalition, Coronavirus, Pandemic, SARS-CoV-2, Solidarity, Systemic crisis, Systemic response",

author = "Charles Auffray and Rudi Balling and Niklas Blomberg and Bonaldo, {Myrna C.} and Bertrand Boutron and Samir Brahmachari and Christian Br{\'e}chot and Alfredo Cesario and Sai-Juan Chen and Karine Cl{\'e}ment and Daria Danilenko and Meglio, {Alberto Di} and Andrea Gelemanovi{\'c} and Carole Goble and Takashi Gojobori and Goldman, {Jason D.} and Michel Goldman and Yi-Ke Guo and James Heath and Leroy Hood and Peter Hunter and Li Jin and Hiroaki Kitano and Bartha Knoppers and Doron Lancet and Catherine Larue and Mark Lathrop and Martine Laville and Lindner, {Ariel B.} and Antoine Magnan and Andres Metspalu and Edgar Morin and Ng, {Lisa F. P.} and Laurent Nicod and Denis Noble and Laurent Nottale and Helga Nowotny and Theresa Ochoa and Okeke, {Iruka N.} and Tolu Oni and Peter Openshaw and Mehmet Ozt{\"u}rk and Susanna Palkonen and Paweska, {Janusz T.} and Christophe Pison and Polymeropoulos, {Mihael H.} and Christian Pristipino and Ulrike Protzer and Josep Roca and Damjana Rozman and Marc Santolini and Ferran Sanz and Giovanni Scambia and Eran Segal and Ismail Serageldin and Soares, {Marcelo Bento} and Peter Sterk and Sumio Sugano and Giulio Superti-Furga and David Supple and Jesper Tegner and Mathias Uhlen and Andrea Urbani and Alfonso Valencia and Vincenzo Valentini and {van der Werf}, Sylvie and Manlio Vinciguerra and Olaf Wolkenhauer and Emiel Wouters",

note = "Funding Information: Grant information: This work was supported during its preparation phases by the State Key Laboratory of Medical Genomics, Overseas Funding Information: This work was supported during its preparation phases by the State Key Laboratory of Medical Genomics, Overseas Expertise Introduction Project for Discipline Innovation [111 Project, B17029] to SJC, LH, CA; European Union grants CASyM [FP7-n?305033] to CA, RB, JR, DR, DS, JT, OW; eTRIKS (IMI-1-n?115446) to CA, RB, YG; PREPARE [FP7-n?602525] to CA, PO, SV; and initial funds in support of the deep phenotyping clinical study from philanthropic donors, Gilead, Merck and Novartis to JG, JH, LH; the Ricerca Corrente Program by the Italian Ministry of Health to AC, CPr, GS, AU, VV; the National Megaprojects of China for Infectious Diseases [2017ZX10103009-001, 2018ZX10305409-001-005], Double First-class projects from the Ministry of Education to the National Research Center for Translational Medicine Shanghai to SJC; Shanghai Municipal Science and Technology Major Project [2017SHZDZX01] to LJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: inventor and holder of two issued patents; JH reports personal fees and other from PACT Pharma, outside the submitted work; HK reports grants from Minister of Health, Welfare, and Labor of Japanese Government, grants from Okinawa Prefecture Government, outside the submitted work; DL reports personal fees from Weizmann Institute of Science and LifeMap Science Inc., outside the submitted work; CL reports personal fees from Genfit, outside the submitted work; PO reports personal fees for consultancy work with Janssen, J&J and Sanofi, grants from MRC, European Union, NIHR Biomedical Research Centre, and a collaborative grant with GSK, outside the submitted work; SP reports grants from Aimmune, Astra Zeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, GSK, Leo Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, outside the submitted work, is employed by the EFA who receives unrestricted grants from corporate entities as above, represents EFA in the following advisory groups of these entities: Astra Zeneca COPD Advisory Committee, GSK Health Advisory Board and Novartis European Patient Advisory Group, receives no personal gain, honoraria, when applicable expenses are payed to her organization, is in a voluntary function the Chair of the Patient Access Partnership PACT who receives unrestricted grants from EFPIA, MedTech Europe, EUCOPE and Medicines for Europe for core operations, and project grants from individual companies, outside the submitted work; CP reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, outside the submitted work; MP reports other from Vanda Pharmaceuticals, outside the submitted work; UP reports grants from VIR Biotechnology, grants and non-financial support from Roche, grants from Alios-J&J, personal fees from Abbvie, Arbutus, Dicerna, Gilead, GSK, MSD, Vaccitech, personal fees from University Hospital Cologne, grants and other from SCG Cell Therapy, outside the submitted work; PS reports other from Breathomix BV, outside the submitted work; GSF reports being a shareholder of Proxygen GmbH, Haplogen GmbH and Allcyte GmbH, outside the submitted work; VV reports personal fees from Merck Serono, Betaglue, outside the submitted work; SvdW reports funding from Sanofi Pasteur, outside the submitted work; she is the holder of four issued patents. The other authors have declared no conflict of interest. Publisher Copyright: {\textcopyright} 2020. Auffray C et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited",

year = "2021",

doi = "https://doi.org/10.12688/F1000RESEARCH.26098.1",

language = "English",

volume = "9",

pages = "1--18",

journal = "F1000Research",

issn = "2046-1402",

publisher = "F1000 Research Ltd.",

}

Auffray, C, Balling, R, Blomberg, N, Bonaldo, MC, Boutron, B, Brahmachari, S, Bréchot, C, Cesario, A, Chen, S-J, Clément, K, Danilenko, D, Meglio, AD, Gelemanović, A, Goble, C, Gojobori, T, Goldman, JD, Goldman, M, Guo, Y-K, Heath, J, Hood, L, Hunter, P, Jin, L, Kitano, H, Knoppers, B, Lancet, D, Larue, C, Lathrop, M, Laville, M, Lindner, AB, Magnan, A, Metspalu, A, Morin, E, Ng, LFP, Nicod, L, Noble, D, Nottale, L, Nowotny, H, Ochoa, T, Okeke, IN, Oni, T, Openshaw, P, Oztürk, M, Palkonen, S, Paweska, JT, Pison, C, Polymeropoulos, MH, Pristipino, C, Protzer, U, Roca, J, Rozman, D, Santolini, M, Sanz, F, Scambia, G, Segal, E, Serageldin, I, Soares, MB, Sterk, P, Sugano, S, Superti-Furga, G, Supple, D, Tegner, J, Uhlen, M, Urbani, A, Valencia, A, Valentini, V, van der Werf, S, Vinciguerra, M, Wolkenhauer, O & Wouters, E 2021, 'COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight', F1000Research, vol. 9, pp. 1-18. https://doi.org/10.12688/F1000RESEARCH.26098.1

TY - JOUR

T1 - COVID-19 and beyond

T2 - a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight

AU - Auffray, Charles

AU - Balling, Rudi

AU - Blomberg, Niklas

AU - Bonaldo, Myrna C.

AU - Boutron, Bertrand

AU - Brahmachari, Samir

AU - Bréchot, Christian

AU - Cesario, Alfredo

AU - Chen, Sai-Juan

AU - Clément, Karine

AU - Danilenko, Daria

AU - Meglio, Alberto Di

AU - Gelemanović, Andrea

AU - Goble, Carole

AU - Gojobori, Takashi

AU - Goldman, Jason D.

AU - Goldman, Michel

AU - Guo, Yi-Ke

AU - Heath, James

AU - Hood, Leroy

AU - Hunter, Peter

AU - Jin, Li

AU - Kitano, Hiroaki

AU - Knoppers, Bartha

AU - Lancet, Doron

AU - Larue, Catherine

AU - Lathrop, Mark

AU - Laville, Martine

AU - Lindner, Ariel B.

AU - Magnan, Antoine

AU - Metspalu, Andres

AU - Morin, Edgar

AU - Ng, Lisa F. P.

AU - Nicod, Laurent

AU - Noble, Denis

AU - Nottale, Laurent

AU - Nowotny, Helga

AU - Ochoa, Theresa

AU - Okeke, Iruka N.

AU - Oni, Tolu

AU - Openshaw, Peter

AU - Oztürk, Mehmet

AU - Palkonen, Susanna

AU - Paweska, Janusz T.

AU - Pison, Christophe

AU - Polymeropoulos, Mihael H.

AU - Pristipino, Christian

AU - Protzer, Ulrike

AU - Roca, Josep

AU - Rozman, Damjana

AU - Santolini, Marc

AU - Sanz, Ferran

AU - Scambia, Giovanni

AU - Segal, Eran

AU - Serageldin, Ismail

AU - Soares, Marcelo Bento

AU - Sterk, Peter

AU - Sugano, Sumio

AU - Superti-Furga, Giulio

AU - Supple, David

AU - Tegner, Jesper

AU - Uhlen, Mathias

AU - Urbani, Andrea

AU - Valencia, Alfonso

AU - Valentini, Vincenzo

AU - van der Werf, Sylvie

AU - Vinciguerra, Manlio

AU - Wolkenhauer, Olaf

AU - Wouters, Emiel

N1 - Funding Information: Grant information: This work was supported during its preparation phases by the State Key Laboratory of Medical Genomics, Overseas Funding Information: This work was supported during its preparation phases by the State Key Laboratory of Medical Genomics, Overseas Expertise Introduction Project for Discipline Innovation [111 Project, B17029] to SJC, LH, CA; European Union grants CASyM [FP7-n?305033] to CA, RB, JR, DR, DS, JT, OW; eTRIKS (IMI-1-n?115446) to CA, RB, YG; PREPARE [FP7-n?602525] to CA, PO, SV; and initial funds in support of the deep phenotyping clinical study from philanthropic donors, Gilead, Merck and Novartis to JG, JH, LH; the Ricerca Corrente Program by the Italian Ministry of Health to AC, CPr, GS, AU, VV; the National Megaprojects of China for Infectious Diseases [2017ZX10103009-001, 2018ZX10305409-001-005], Double First-class projects from the Ministry of Education to the National Research Center for Translational Medicine Shanghai to SJC; Shanghai Municipal Science and Technology Major Project [2017SHZDZX01] to LJ. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding Information: inventor and holder of two issued patents; JH reports personal fees and other from PACT Pharma, outside the submitted work; HK reports grants from Minister of Health, Welfare, and Labor of Japanese Government, grants from Okinawa Prefecture Government, outside the submitted work; DL reports personal fees from Weizmann Institute of Science and LifeMap Science Inc., outside the submitted work; CL reports personal fees from Genfit, outside the submitted work; PO reports personal fees for consultancy work with Janssen, J&J and Sanofi, grants from MRC, European Union, NIHR Biomedical Research Centre, and a collaborative grant with GSK, outside the submitted work; SP reports grants from Aimmune, Astra Zeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, GSK, Leo Pharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, outside the submitted work, is employed by the EFA who receives unrestricted grants from corporate entities as above, represents EFA in the following advisory groups of these entities: Astra Zeneca COPD Advisory Committee, GSK Health Advisory Board and Novartis European Patient Advisory Group, receives no personal gain, honoraria, when applicable expenses are payed to her organization, is in a voluntary function the Chair of the Patient Access Partnership PACT who receives unrestricted grants from EFPIA, MedTech Europe, EUCOPE and Medicines for Europe for core operations, and project grants from individual companies, outside the submitted work; CP reports personal fees and non-financial support from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, outside the submitted work; MP reports other from Vanda Pharmaceuticals, outside the submitted work; UP reports grants from VIR Biotechnology, grants and non-financial support from Roche, grants from Alios-J&J, personal fees from Abbvie, Arbutus, Dicerna, Gilead, GSK, MSD, Vaccitech, personal fees from University Hospital Cologne, grants and other from SCG Cell Therapy, outside the submitted work; PS reports other from Breathomix BV, outside the submitted work; GSF reports being a shareholder of Proxygen GmbH, Haplogen GmbH and Allcyte GmbH, outside the submitted work; VV reports personal fees from Merck Serono, Betaglue, outside the submitted work; SvdW reports funding from Sanofi Pasteur, outside the submitted work; she is the holder of four issued patents. The other authors have declared no conflict of interest. Publisher Copyright: © 2020. Auffray C et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

PY - 2021

Y1 - 2021

N2 - Background: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) belongs to a subgroup of coronaviruses rampant in bats for centuries. It caused the coronavirus disease 2019 (COVID-19) pandemic. Most patients recover, but a minority of severe cases experience acute respiratory distress or an inflammatory storm devastating many organs that can lead to patient death. The spread of SARS-CoV-2 was facilitated by the increasing intensity of air travel, urban congestion and human contact during the past decades. Until therapies and vaccines are available, tests for virus exposure, confinement and distancing measures have helped curb the pandemic. Vision: The COVID-19 pandemic calls for safeguards and remediation measures through a systemic response. Self-organizing initiatives by scientists and citizens are developing an advanced collective intelligence response to the coronavirus crisis. Their integration forms Olympiads of Solidarity and Health. Their ability to optimize our response to COVID-19 could serve as a model to trigger a global metamorphosis of our societies with far-reaching consequences for attacking fundamental challenges facing humanity in the 21st century. Mission: For COVID-19 and these other challenges, there is no alternative but action. Meeting in Paris in 2003, we set out to "rethink research to understand life and improve health." We have formed an international coalition of academia and industry ecosystems taking a systems medicine approach to understanding COVID-19 by thoroughly characterizing viruses, patients and populations during the pandemic, using openly shared tools. All results will be publicly available with no initial claims for intellectual property rights. This World Alliance for Health and Wellbeing will catalyze the creation of medical and health products such as diagnostic tests, drugs and vaccines that become common goods accessible to all, while seeking further alliances with civil society to bridge with socio-ecological and technological approaches that characterise urban systems, for a collective response to future health emergencies.

AB - Background: Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) belongs to a subgroup of coronaviruses rampant in bats for centuries. It caused the coronavirus disease 2019 (COVID-19) pandemic. Most patients recover, but a minority of severe cases experience acute respiratory distress or an inflammatory storm devastating many organs that can lead to patient death. The spread of SARS-CoV-2 was facilitated by the increasing intensity of air travel, urban congestion and human contact during the past decades. Until therapies and vaccines are available, tests for virus exposure, confinement and distancing measures have helped curb the pandemic. Vision: The COVID-19 pandemic calls for safeguards and remediation measures through a systemic response. Self-organizing initiatives by scientists and citizens are developing an advanced collective intelligence response to the coronavirus crisis. Their integration forms Olympiads of Solidarity and Health. Their ability to optimize our response to COVID-19 could serve as a model to trigger a global metamorphosis of our societies with far-reaching consequences for attacking fundamental challenges facing humanity in the 21st century. Mission: For COVID-19 and these other challenges, there is no alternative but action. Meeting in Paris in 2003, we set out to "rethink research to understand life and improve health." We have formed an international coalition of academia and industry ecosystems taking a systems medicine approach to understanding COVID-19 by thoroughly characterizing viruses, patients and populations during the pandemic, using openly shared tools. All results will be publicly available with no initial claims for intellectual property rights. This World Alliance for Health and Wellbeing will catalyze the creation of medical and health products such as diagnostic tests, drugs and vaccines that become common goods accessible to all, while seeking further alliances with civil society to bridge with socio-ecological and technological approaches that characterise urban systems, for a collective response to future health emergencies.

KW - COVID-19

KW - Coalition

KW - Coronavirus

KW - Pandemic

KW - SARS-CoV-2

KW - Solidarity

KW - Systemic crisis

KW - Systemic response

UR - http://www.scopus.com/inward/record.url?scp=85117310496&partnerID=8YFLogxK

U2 - https://doi.org/10.12688/F1000RESEARCH.26098.1

DO - https://doi.org/10.12688/F1000RESEARCH.26098.1

M3 - Article

SN - 2046-1402

VL - 9

SP - 1

EP - 18

JO - F1000Research

JF - F1000Research

ER -

COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight

Abstract

Keywords

Access to Document

Other files and links

Cite this